Divozilimab
Highest phase reached
Phase 3
Drug type
Antibody
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Antibody
- Drug name
- Divozilimab
- divozilimab
- Divozilimab
- divozilimab [INN]
- Divozilimab [WHO-DD]
- divozilimab inn
- divozilimab who dd
- immunoglobulin g1 anti human cd20 antigen human mus musculus monoclonal bcd 132 gamma 1 chain disulfide with human mus musculus monoclonal bcd 132 kappa chain dimer
- IMMUNOGLOBULIN G1, ANTI-(HUMAN CD20 ANTIGEN) (HUMAN-MUS MUSCULUS MONOCLONAL BCD-132 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BCD-132 .KAPPA.-CHAIN, DIMER
- ATC classification codes
- L04AG15
Sources for recorded values
- CAS registry numbers
- 2254061-60-2
- ChEMBL ID
- CHEMBL5314981
- FDA ingredient codes (UNII)
- 13ZEQ1M5ML
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- divozilimab
- Type
- Antibody
- Drug name stem
- -mab
- Approval recorded by Guide to Pharmacology
- Yes
Mechanisms of action
- Action
- Antibody
- Action type
- ANTIBODY
- Target
- CD20 (membrane-spanning 4-domains, subfamily A, member 1)
- Gene symbol
- MS4A1
- Protein identifier
- P11836
- Primary target
- Yes
- Condition
- Scleroderma, Systemic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000717
- Subject identifier
- D012595
- Condition
- Neuromyelitis Optica
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004256
- Subject identifier
- D009471
- Condition identifier
- EFO_0000717
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004256
- Highest recorded phase
- 3
- Condition identifier
- EFO_0803536
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005100
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005301
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0007915
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0019100
- Highest recorded phase
- 3
- NCT05726630
- NCT05730699
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (4)
- An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD
- Clinical Study of Divozilimab in Patients With Systemic Scleroderma
- Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)
- Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus
In development for (4)
- Multiple sclerosis Phase 3
- Neuromyelitis optica Phase 3
- Systemic lupus erythematosus Phase 1
- Systemic sclerosis Phase 3